What Is Chronic Inflammation

Chronic inflammation is a persistent, low-level activation of the immune system that continues for months or years without a clear acute trigger. Unlike the short-lived inflammation that heals a wound or fights an infection, chronic inflammation slowly damages tissues, disrupts organ function, and accelerates biological aging. It operates silently, often producing no obvious symptoms until downstream diseases like atherosclerosis, type 2 diabetes, or neurodegeneration have already taken hold.

Chronic inflammation sits at the intersection of nearly every age-related disease. Cardiovascular disease, cancer, Alzheimer's disease, type 2 diabetes, and osteoarthritis all share elevated inflammatory signaling as a common mechanistic thread. Epidemiological data consistently link higher levels of circulating inflammatory markers with shorter lifespan and greater disability in older adults. Within the hallmarks of aging framework, chronic inflammation (sometimes called inflammaging) acts as both a consequence of other hallmarks and an amplifier of them. Senescent cells secrete pro-inflammatory molecules, mitochondrial dysfunction releases damage-associated molecular patterns, and genomic instability triggers immune surveillance responses; each of these feeds back into the inflammatory loop.

Because chronic inflammation is both measurable and modifiable, it represents one of the most actionable targets in longevity science. Reducing systemic inflammatory tone does not require a single intervention; it responds to changes across sleep, movement, nutrition, stress, and environmental exposure. This makes it a useful barometer for overall biological health and a meaningful outcome to track when evaluating any longevity strategy.

The immune system uses inflammation as a repair and defense mechanism. When tissue is damaged or a pathogen enters the body, immune cells release signaling molecules called cytokines (including interleukin-1, interleukin-6, and tumor necrosis factor alpha) that recruit more immune cells, increase blood flow, and initiate tissue repair. In a healthy acute response, anti-inflammatory signals follow to resolve the process once the threat is handled.

Chronic inflammation arises when the resolution phase fails or when low-level triggers persist. Visceral adipose tissue, for example, behaves as an endocrine organ that continuously secretes IL-6 and TNF-alpha. Senescent cells that resist clearance produce a cocktail of inflammatory molecules known as the senescence-associated secretory phenotype (SASP). A permeable intestinal barrier allows bacterial components like lipopolysaccharide (LPS) to enter the bloodstream, activating toll-like receptors on immune cells and sustaining NF-kB signaling, the master transcription factor for inflammatory gene expression. Mitochondria that are damaged or dysfunctional release their own DNA into the cytoplasm, where it is recognized as a danger signal by the innate immune system through the cGAS-STING pathway.

Over time, sustained NF-kB activation and elevated cytokine levels create a self-reinforcing cycle. Inflammatory signaling impairs insulin sensitivity, promotes endothelial dysfunction, degrades cartilage, damages neurons, and disrupts the hypothalamic-pituitary-adrenal axis. These downstream effects generate further cellular damage, which in turn stimulates more inflammation. This feedback architecture is why chronic inflammation tends to worsen with age rather than spontaneously resolve, and why it requires deliberate intervention at multiple inputs to interrupt.

The link between chronic inflammation and aging has been studied extensively through epidemiological cohorts, mechanistic cell biology, and clinical trials. Large observational studies consistently show that elevated hsCRP and IL-6 predict cardiovascular events, cognitive decline, frailty, and all-cause mortality in older adults. Mechanistic work has mapped the NF-kB, cGAS-STING, and inflammasome pathways in detail, establishing how cellular damage signals sustain immune activation. The CANTOS trial (a large-scale randomized controlled trial using an anti-IL-1 beta antibody) demonstrated that reducing inflammation independent of lipid levels lowered cardiovascular event rates, providing direct causal evidence that inflammatory signaling itself drives disease rather than merely correlating with it.

Gaps remain in understanding the optimal degree of immune suppression versus modulation. Broad anti-inflammatory approaches carry infection risk, as CANTOS also showed a modest increase in fatal infections. Whether specific dietary patterns, exercise protocols, or senolytic interventions can achieve the same targeted cytokine reductions without immunosuppression is an active area of investigation. Most supplement-based anti-inflammatory claims (curcumin, omega-3, resveratrol) have supportive mechanistic data and small clinical trials, but few have been validated in large, long-duration randomized trials with hard clinical endpoints. The field is converging on the idea that multi-modal lifestyle intervention, rather than any single agent, offers the most reliable inflammatory reduction with the fewest trade-offs.

Inflammation is not inherently harmful; acute inflammatory responses are essential for wound healing, pathogen clearance, and tissue remodeling. Overly aggressive suppression of immune function, whether through chronic NSAID use, high-dose immunosuppressants, or poorly supervised anti-inflammatory regimens, can impair infection defense and slow recovery from injury. Some individuals with persistently elevated inflammatory markers may have undiagnosed autoimmune conditions, chronic infections, or environmental exposures that require specific diagnosis rather than general anti-inflammatory strategies. Anyone with hsCRP consistently above 3.0 mg/L should work with a clinician to rule out treatable underlying causes before attributing the finding to general aging.